Phenomix rises with $7.8m to advance obesity precision medicine

Company’s technology predicts how patients will respond to weight loss interventions by identifying specific obesity phenotypes.

Precision medicine biotech Phenomix Sciences has raised $7.8 million in new funding to advance its obesity phenotyping technology and conduct further clinical research in weight loss treatment.

Obesity is linked to multiple chronic diseases and significant reductions in life expectancy, but treating it effectively is not a one-size-fits-all approach. Founded by Mayo Clinic physicians and researchers Dr Andres Acosta and Dr Michael Camilleri, Phenomix aims to address the variability in patient responses to obesity treatments through its proprietary genetic tests and data analytics.

Phenomix has develop the MyPhenome test, which helps predict individual patient responses to weight loss interventions by identifying specific obesity phenotypes such as Hungry Gut, Hungry Brain, and Emotional Hunger. The test is currently being used by providers in the US as a tool for developing personalized treatment plans that include lifestyle changes, dietary adjustments, medications, and procedural recommendations.

The new funding will accelerate the commercialization of the MyPhenome test, as well as supporting the development of additional phenotyping tests, ongoing clinical studies, patenting new insights, and building strategic partnerships with pharmaceutical companies and healthcare providers.

The SBIR grant from the NIH will specifically fund a prospective study to further validate the MyPhenome test’s effectiveness in predicting treatment responses, underscoring the significance of Phenomix’s work and the reputation of its founders.

The new funding includes $5.5 million from a Series A venture round, welcoming new strategic investors DexCom and Labcorp alongside existing backers. The company also received a $2.3 million Phase II Small Business Innovation Research grant from the National Institutes of Health.

“As leaders in their respective fields of lab testing and patient empowerment, we are excited to add DexCom and Labcorp as investors as we continue to scale our company,” said Mark Bagnall, CEO of Phenomix. “After more than a decade of research from our founders, we are thrilled the wider industry is also seeing the need to treat the obesity epidemic seriously with clinically focused solutions.”

Photograph: puhimec/Envato